US9908875B2 - Apoptosis signal-regulating kinase inhibitors - Google Patents

Apoptosis signal-regulating kinase inhibitors Download PDF

Info

Publication number
US9908875B2
US9908875B2 US15/105,372 US201415105372A US9908875B2 US 9908875 B2 US9908875 B2 US 9908875B2 US 201415105372 A US201415105372 A US 201415105372A US 9908875 B2 US9908875 B2 US 9908875B2
Authority
US
United States
Prior art keywords
cyclopropyl
triazol
thiazol
alkyl
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/105,372
Other languages
English (en)
Other versions
US20160318922A1 (en
Inventor
Gregory Notte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52282961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US9908875(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority to US15/105,372 priority Critical patent/US9908875B2/en
Publication of US20160318922A1 publication Critical patent/US20160318922A1/en
Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOTTE, GREGORY
Application granted granted Critical
Publication of US9908875B2 publication Critical patent/US9908875B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to novel compounds having enzyme inhibitory activity, and to their use in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, including chronic kidney disease, cardiovascular diseases and neurodegenerative diseases.
  • the invention also relates to methods for their preparation, and to pharmaceutical compositions containing such compounds.
  • Mitogen-activated protein kinase (MAPK) signaling cascades couple diverse extracellular and intracellular queues to appropriate cellular stress responses, including cell growth, differentiation, inflammation, and apoptosis (Kumar, S., Boehm, J., and Lee., J. C. (2003) Nat. Rev. Drug Dis. 2:717-726; Pimienta, G., and Pascual, J. (2007) Cell Cycle, 6: 2826-2632).
  • MAPKs exist in three groups, MAP3Ks, MAP2Ks, and MAPKs, which are sequentially activated.
  • MAPK3s directly respond to environmental signals and phosphorylate MAP2Ks, which in turn phosphorylate specific MAPKs.
  • MAPKs then mediated the appropriate cellular response by phosphorylating cellular substrates, including transcription factors that regulate gene expression.
  • Apoptosis signal-regulating kinase 1 is a member of the mitogen-activated protein kinase kinase kinase (“MAP3K”) family that activates the c-Jun N-terminal protein kinase (“JNK”) and p38 MAP kinase (Ichijo, H., Nishida, E., Irie, K., Dijke, P. T., Saitoh, M., Moriguchi, T., Matsumoto, K., Miyazono, K., and Gotoh, Y. (1997) Science, 275, 90-94).
  • MAP3K mitogen-activated protein kinase kinase kinase kinase
  • JNK c-Jun N-terminal protein kinase
  • JNK c-Jun N-terminal protein kinase
  • ASK1 is activated by a variety of stimuli including oxidative stress, reactive oxygen species (ROS), LPS, TNF- ⁇ , FasL, ER stress, and increased intracellular calcium concentrations (Hattori, K., Naguro, I., Runchel, C., and Ichijo, H. (2009) Cell Comm Signal. 7:1-10; Takeda, K., Noguchi, T., Naguro, I., and Ichijo, H. (2007) Annu. Rev. Pharmacol. Toxicol. 48: 1-8.27; Nagai, H., Noguchi, T., Takeda, K., and Ichijo, I. (2007) J. Biochem. Mol. Biol. 40:1-6).
  • ROS reactive oxygen species
  • ASK1 undergoes activation via autophosphorylation at Thr838 in response to these signals and in turn phosphorylates MAP2Ks, such as MKK3/6 and MKK4/7, which then phosphorylate and activates p38 and JNK MAPKs, respectively.
  • ASK2 is a related MAP3K that shares 45% sequence homology with ASK1 (Wang, X. S., Diener, K., Tan, T-H., and Yao, Z. (1998) Biochem. Biophys. Res. Commun. 253, 33-37.
  • ASK2 tissue distribution is restricted, in some cell types ASK1 and ASK2 have been reported to interact and function together in a protein complex (Takeda, K., Shimozono, R., Noguchi, T., Umeda, T., Morimoto, Y., Naguro, I., Tobiume, K., Saitoh, M., Matsuzawa, A., and Ichijo, H. (2007) J. Biol. Chem. 282: 7522-7531; Iriyama, T., et al. (2009) Embo J.
  • ASK1 is kept in an inactive state through binding to its repressor Thioredoxin (Trx) (Saitoh, M., Nishitoh, H., Fuji, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., Miyazono, K., and Ichijo, H. (1998) Embo J. 17:2596-2606), and through association with AKT (Zhang, L., Chen, J. and Fu, H. (1999) Proc. Natl. Acad. Sci. U.S.A 96:8511-8515).
  • Trx Thioredoxin
  • ASK1 activation and signaling have been reported to play an important role in a broad range of diseases including neurodegenerative, cardiovascular, inflammatory, autoimmunity, and metabolic disorders.
  • ASK1 has been implicated in mediating organ damage following ischemia and reperfusion of the heart, brain, and kidney (Watanabe et al. (2005) BBRC 333, 562-567; Zhang et al., (2003) Life Sci 74-37-43; Terada et al. (2007) BBRC 364: 1043-49).
  • ASK2 either alone or in a complex with ASK1
  • ASK2 signaling complexes have the potential to remedy or improve the lives of patients suffering from such conditions.
  • U.S. Publication No. 2007/0276050 describes methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular disease and methods for preventing and/or treating cardiovascular disease in an animal.
  • the methods comprise administering to the animal an ASK1 inhibitor and, optionally, a hypertensive compound.
  • U.S. Publication No. 2007/0167386 reports a drug for at least one of prevention and treatment of cardiac failure containing a compound that inhibits a functional expression of ASK1 protein in a cardiomyocyte, and a method for screening the drug.
  • WO2009027283 discloses triazolopyridine compounds, methods for preparation thereof and methods for treating autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases.
  • the present invention provides novel compounds that function as ASK1 inhibitors, compositions and methods of using said novel compounds.
  • the application relates to compounds of Formula (I):
  • R 1 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, wherein the alkyl, cycloalkyl, or heterocycloalkyl moiety is optionally substituted with one to four members independently selected from the group consisting of halo, oxo, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, phenyl, phenoxy, cyano, OR 11 , C(O)R 11 , OC(O)R 11 , C(O)OR 11 , N(R 11 )C(O)OR 12 , N(R 11 )C(O)R 12 , NR 11 R 12 , N(R 11 )C(O)N(R 11 )(R 12 ), C(O)N(R 11 )(R 12 ), C 1 -C 6 alkyl-R 11 ,
  • R 2 is hydrogen or C 1 -C 6 alkyl wherein the alkyl moiety is optionally substituted with one to four members of halogen atoms;
  • R 3 is hydrogen or C 1 -C 6 alkyl
  • R 4 is hydrogen or C 1 -C 6 alkyl
  • R 5 is hydrogen or C 1 -C 6 alkyl
  • R 6 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, wherein the alkyl, cycloalkyl, or heterocycloalkyl moiety is optionally substituted with one to four members independently selected from the group consisting of halo, oxo, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, phenyl, phenoxy, cyano, OR 11 , NR 11 R 12 , C(O)R 11 , OC(O)R 11 , C(O)OR 11 , N(R 11 )C(O)OR 12 , N(R 11 )C(O)R 12 , N(R 11 )C(O)N(R 11 )(R 12 ), C(O)N(R 11 )(R 12 ), C 1 -C 6 alkyl-R 11 ,
  • R 7 is hydrogen or C 1 -C 6 alkyl
  • R a and R b are independently hydrogen, C 1 -C 6 alkyl, or R a and R b combine with the nitrogen atom to which they are attached to form a three to twelve member heterocyclic group, wherein the heterocyclic group is a monocyclic, fused or bridged bicyclic, or spirocyclic group optionally substituted with an oxygen or nitrogen atom in the ring, wherein the C 1 -C 6 alkyl or the heterocyclic group is further optionally substituted with one to four members independently selected from the group consisting of C 1 -C 6 alkyl, hydroxyl, cyano, oxo, halo, phenyl, phenoxy, C 1 -C 6 carbonyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, C 1 -C 6 alkyl-R 11 , OR 11 , NR 11 R
  • the present application relates to a method of using the compounds of Formula (I) in the treatment of a disease or condition in a patient which is amenable to treatment by an ASK1 inhibitor.
  • diseases include autoimmune disorders, inflammatory diseases, cardiovascular diseases (including diabetes, diabetic nephropathy, and other complications of diabetes), cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases (including COPD, idiopathic pulmonary fibrosis (IPF), and acute lung injury), acute and chronic liver diseases, and neurodegenerative diseases.
  • the application relates to pharmaceutical composition
  • the present application provides a compound of formula (I) useful for treating chronic kidney disease, kidney fibrosis and lung fibrosis
  • the application provides a method of treating a patient in need thereof with a therapeutically effective amount of compound of Formula (I) and a therapeutic effective amount of one or more therapeutic agent.
  • the disclosure provides a compound of formula (I) for use in therapy.
  • the disclosure relates to the use of a compound of formula (I) for the manufacture of a medicament for treating autoimmune disorders, inflammatory diseases, cardiovascular diseases (including diabetes, diabetic nephropathy, and other complications of diabetes), cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases (including COPD, idiopathic pulmonary fibrosis (IPF), and acute lung injury), acute and chronic liver diseases, and neurodegenerative diseases.
  • cardiovascular diseases including diabetes, diabetic nephropathy, and other complications of diabetes
  • cardio-renal diseases including kidney disease, fibrotic diseases, respiratory diseases (including COPD, idiopathic pulmonary fibrosis (IPF), and acute lung injury), acute and chronic liver diseases, and neurodegenerative diseases.
  • cardiovascular diseases including diabetes, diabetic nephropathy, and other complications of diabetes
  • cardio-renal diseases including kidney disease, fibrotic diseases, respiratory diseases (including COPD, idiopathic pulmonary fibrosis (IPF), and acute lung injury), acute and chronic liver diseases, and neurode
  • the disclosure relates to the kit comprises the compounds of Formula (I) or pharmaceutical composition thereof.
  • the kit comprises a label or instruction of use.
  • alkyl refers to a monoradical branched or unbranched saturated hydrocarbon chain having the indicated number of carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl and the like.
  • substituted alkyl refers to an alkyl group as defined above, having 1, 2, 3 or more substituents selected from the indicated groups.
  • alkylene refers to a diradical of a branched or unbranched saturated hydrocarbon chain, typically having from 1 to 6 carbon atoms (e.g. 1, 2, 3, 4, 5 or 6 carbon atoms). This term is exemplified by groups such as methylene (—CH 2 —), ethylene (—CH 2 CH 2 —), the propylene isomers (e.g., —CH 2 CH 2 CH 2 — and —CH(CH 3 )CH 2 —), and the like.
  • amino refers to the group —NH 2 .
  • substituted amino refers to an NHR a , NR a R b , or NR 11 R 12 group wherein R a , R b , R 11 and R 12 (which may be same or different) represent the substituent groups.
  • cycloalkyl refers to cyclic alkyl groups of from 3 to 6 carbon atoms having a single cyclic ring.
  • Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, and the like.
  • halogen refers to fluoro, bromo, chloro, and iodo.
  • haloalkyl refers to alkyl of 1-4 (or as indicated) carbon atoms substituted by 1, 2, 3, or 4 halo atoms or as chemically permissible. Where a residue or member is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached.
  • dihaloaryl, dihaloalkyl, and trihaloaryl refer to aryl and alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, the same halogen; thus, for example, 3,5-difluorophenyl, 3-chloro-5-fluorophenyl, 4-chloro-3-fluorophenyl, and 3,5-difluoro-4-chlorophenyl is within the scope of dihaloaryl.
  • haloalkyl groups include, but is not limited to, fluoromethyl, difluoromethyl (—CHF 2 ), trifluoromethyl (—CF 3 ), fluoroethyl, difluoroethyl, trifluoroethyl, perfluoroethyl, fluoropropyl, difluoropropyl, trifluoropropyl, perfluoropropyl, fluorobutyl, and perfluorobutyl.
  • trifluoropropyl compasses fluoro-substitutions at any carbon position and includes, but not limited to, 1,1,1-trifluropropanyl and 1,1,1-trifluoroisopropanyl.
  • acyl denotes a group —C(O)R, in which R is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
  • acylhalide refers to the group —C(O)X where X is a halogen atom preferably chloro.
  • heterocyclyl refers to a saturated or partially unsaturated cyclic group having a single ring or multiple rings that are fused, bridged, or spirocyclic.
  • Heterocyclic groups comprise 1 to 12 carbon atoms and 1 to 3 hetero atoms selected from nitrogen, sulfur, and/or oxygen within the ring.
  • the term “seven to ten membered heterocyclic” refers to a heterocyclic group as defined above wherein the total number of ring members is seven to ten and adjustment is made for the number of carbon atoms based on the number of heteroatoms in the ring.
  • heterocyclic bicyclic group refers to a heterocyclic bicyclic group that may be fused, bridged, or spirocyclic as indicated, wherein the total number of ring members is six to ten and adjustment is made for the number of carbon atoms based on the number of heteroatoms in the ring.
  • heterocyclic groups include morpholino, piperidinyl, piperazino, dihydropyridino, and the like.
  • alkoxy refers to the group “alkyl-O—.” Examples of alkoxy groups may include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.
  • aryl refers to an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl) or multiple fused rings (e.g., naphthyl, fluorenyl, and anthryl).
  • Aryl groups have 6 to 20 ring carbon atoms (i.e., C 6-20 aryl), or 6 to 12 carbon ring atoms (i.e., C 6-12 aryl). If one or more aryl groups are fused with a heteroaryl ring, the resulting ring system is heteroaryl.
  • substituted means that any one or more hydrogen atoms on the designated atom or group is replaced with a moiety other than hydrogen, provided that the designated atom's normal valence is not exceeded.
  • the substituted member or group may be located on any position of the designated atom or group.
  • the heterocyclic group e.g. 1,4-oxazepanyl
  • the cyano member may be located at any position of the heterocyclic group.
  • a dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, —CONH 2 is attached through the carbon atom.
  • references to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X”.
  • a compound of a given Formula (e.g. the “compound of Formula (I)”) is intended to encompass the representative compounds disclosed herein, and the pharmaceutically acceptable salts, pharmaceutically acceptable esters, hydrates, polymorphs, and prodrugs of such compounds.
  • the present application also includes compounds of Formula (I) in which one or more hydrogen atoms attached to a carbon atom is/are replaced by deuterium.
  • Such compounds exhibit increased resistance to metabolism, and are thus useful for increasing the half life of any compound of Formula I when administered to a mammal. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism”, Trends Pharmacol. Sci. 5(12):524-527 (1984).
  • Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
  • isomers refers to different compounds that have the same molecular formula.
  • stereoisomers refers to isomers that differ only in the way the atoms are arranged in space. As commonly referred in the art, stereoisomers may be enantiomers or diastereoisomers.
  • enantiomers refers to a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture.
  • ( ⁇ )” is used to designate a racemic mixture where appropriate.
  • diastereoisomers refers to stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
  • therapeutically effective amount refers to an amount that is sufficient to effect treatment, as defined below, when administered to a mammalian patient, such as a human patient, in need of such treatment.
  • the therapeutically effective amount will vary depending upon the subject (e.g. a human) and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
  • treatment refers to any administration of a compound of the present application or practice of the method of the present application for the purpose of (i) protecting against the disease, that is, causing the clinical symptoms of the disease not to develop; (ii) inhibiting the disease, that is, arresting the development of clinical symptoms; and/or (iii) relieving the disease, that is, causing the regression of clinical symptoms.
  • the compounds described herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • pharmaceutically acceptable salt of a given compound refers to salts that retain the biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable.
  • Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines and the like. Also included are amines where the two or three substituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group.
  • Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • Chronic diseases or “cardiovascular diseases” refer to diseases of the cardiovasculature arising from any one or more than one of, for example, heart failure (including congestive heart failure, diastolic heart failure and systolic heart failure), acute heart failure, ischemia, recurrent ischemia, myocardial infarction, arrhythmias, angina (including exercise-induced angina, variant angina, stable angina, unstable angina), acute coronary syndrome, diabetes, and intermittent claudication.
  • heart failure including congestive heart failure, diastolic heart failure and systolic heart failure
  • acute heart failure ischemia, recurrent ischemia, myocardial infarction, arrhythmias
  • angina including exercise-induced angina, variant angina, stable angina, unstable angina
  • acute coronary syndrome diabetes, and intermittent claudication.
  • Intermittent claudication means the pain associated with peripheral artery disease.
  • Peripheral artery disease or PAD is a type of occlusive peripheral vascular disease (PVD). PAD affects the arteries outside the heart and brain. The most common symptom of PAD is a painful cramping in the hips, thighs, or calves when walking, climbing stairs, or exercising. The pain is called intermittent claudication. When listing the symptom intermittent claudication, it is intended to include both PAD and PVD.
  • arrhythmia refers to any abnormal heart rate.
  • Bradycardia refers to abnormally slow heart rate whereas tachycardia refers to an abnormally rapid heart rate.
  • the treatment of arrhythmia is intended to include the treatment of supra ventricular tachycardias such as atrial fibrillation, atrial flutter, AV nodal reentrant tachycardia, atrial tachycardia, and the ventricular tachycardias (VTs), including idiopathic ventricular tachycardia, ventricular fibrillation, pre-excitation syndrome, and Torsade de Pointes (TdP).
  • supra ventricular tachycardias such as atrial fibrillation, atrial flutter, AV nodal reentrant tachycardia, atrial tachycardia, and the ventricular tachycardias (VTs), including idiopathic ventricular tachycardia, ventricular fibrillation, pre
  • “Pharmaceutically-acceptable” means suitable for use in pharmaceutical preparations, generally considered as safe for such use, officially approved by a regulatory agency of a national or state government for such use, or being listed in the U. S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.
  • Prodrug refers a compound that is chemically designed to efficiently liberate the parent drug after overcoming biological barriers to oral delivery.
  • Polymorph refers to the different crystal forms of a compound, resulting from the possibility of at least two different arrangements of the molecules of the compound in the solid state. Polymorphs of a given compound will be different in crystal structure but identical in liquid or vapor states. Different polymorphic forms of a given substance may differ from each other with respect to one or more physical properties, such as solubility and dissociation, true density, crystal shape, compaction behavior, flow properties, and/or solid state stability.
  • physical properties such as solubility and dissociation, true density, crystal shape, compaction behavior, flow properties, and/or solid state stability.
  • R 1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, wherein the alkyl, cycloalkyl, or heterocycloalkyl moiety is optionally substituted with one to four members independently selected from the group consisting of halo, oxo, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, phenyl, phenoxy, cyano, OR 11 , C(O)R 11 , OC(O)R 11 , C(O)OR 11 , N(R 11 )C(O)OR 12 , N(R 11 )C(O)R 12 , N(R 11 )C(O)N(R 11 )(R 12 ), C(O)N(R 11 )(R 12 ), NR 11 R 12 , C 1 -C 6 alkyl-R 11 , C 1
  • R 2 is hydrogen or C 1 -C 6 alkyl wherein the alkyl moiety is optionally substituted with one to four members of halogen atoms;
  • R 3 is hydrogen or C 1 -C 6 alkyl
  • R 4 is hydrogen or C 1 -C 6 alkyl
  • R 5 is hydrogen or C 1 -C 6 alkyl
  • R 6 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, wherein the alkyl, cycloalkyl, or heterocycloalkyl moiety is optionally substituted with one to four members independently selected from the group consisting of halo, oxo, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, phenyl, phenoxy, cyano, OR 11 , C(O)R 11 , OC(O)R 11 , C(O)OR 11 , N(R 11 )C(O)OR 12 , N(R 11 )C(O)R 12 , N(R 11 )C(O)N(R 11 )(R 12 ), NR 11 R 12 , C(O)N(R 11 )(R 12 ), C 1 -C 6 alkyl-R 11 ,
  • R 7 is hydrogen or C 1 -C 6 alkyl
  • R a and R b are independently hydrogen, C 1 -C 6 alkyl, or R a and R b combine with the nitrogen atom to which they are attached to form a three to twelve member heterocyclic group, wherein the heterocyclic group is a monocyclic, fused or bridged bicyclic, or spirocyclic group optionally substituted with an oxygen or nitrogen atom in the ring, wherein the C 1 -C 6 alkyl or the heterocyclic group is further optionally substituted with one to four members, on the same or different atom/location, independently selected from the group consisting of C 1 -C 6 alkyl, hydroxyl, cyano, oxo, halo, phenyl, phenoxy, C 1 -C 6 carbonyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, C 1 -C 6 acyl, C
  • the present application provides the compound of Formula (I), wherein
  • R 1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or C 2 -C 6 heterocycloalkyl, wherein the alkyl, cycloalkyl, or heterocycloalkyl moiety is optionally substituted with one to four members independently selected from halo, OR 11 , and NR 11 R 12 ;
  • R 2 is hydrogen or C 1 -C 3 alkyl
  • R 3 is hydrogen or C 1 -C 3 alkyl
  • R 4 is hydrogen or C 1 -C 3 alkyl
  • R 5 is hydrogen or C 1 -C 3 alkyl
  • R 6 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or C 2 -C 6 heterocycloalkyl, wherein the alkyl, cycloalkyl, or heterocycloalkyl moiety is optionally substituted with one to four members independently selected from halo, OR 11 , and NR 11 R 12
  • R 7 is hydrogen or C 1 -C 3 alkyl
  • R a and R b combine with the nitrogen atom to which they are attached to form a four to ten member heterocyclic group that is a monocyclic group or a fused or bridged bicyclic, or spirocyclic group optionally containing an oxygen or a nitrogen atom in the heterocyclic group, wherein the heterocyclic is further optionally substituted with one to four members, at the same or different atom/location, independently selected from C 1 -C 6 alkyl, hydroxyl, cyano, oxo, halo, C 1 -C 6 carbonyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, C 1 -C 6 acyl, C 1 -C 6 alkyl-R 11 , OR 11 , C(O)NR 11 wherein R 11 is hydrogen, C 1 -C 6 alkyl, or C 1 -C 6
  • R 1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or C 2 -C 6 heterocycloalkyl, wherein the alkyl, cycloalkyl, or heterocycloalkyl moiety is optionally substituted with one to four halogen atoms;
  • R 2 is hydrogen or C 1 -C 3 alkyl
  • R 3 is hydrogen or C 1 -C 3 alkyl
  • R 4 is hydrogen or C 1 -C 3 alkyl
  • R 5 is hydrogen or C 1 -C 3 alkyl
  • R 6 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or C 2 -C 6 heterocycloalkyl, wherein the alkyl, cycloalkyl, or heterocycloalkyl moiety is optionally substituted with one to four halogen atoms;
  • R 7 is hydrogen or C 1 -C 3 alkyl
  • R a and R b combine with the nitrogen atom to which they are attached to form a four to ten member heterocyclic monocyclic group optionally containing an oxygen or a nitrogen atom, or a six to twelve member heterocyclic fused or bridged bicyclic or spirocyclic group optionally containing an oxygen or a nitrogen atom in the heterocyclic monocyclic, bicyclic or spirocyclic group, wherein the heterocyclic monocyclic, bicyclic or spirocyclic group is further optionally substituted with one to four members independently selected from C 1 -C 6 alkyl, hydroxyl, cyano, oxo, halo, C 1 -C 6 carbonyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, C 1 -C 6 acyl, C 1 -C 6 alkyl-R 11 , OR 11
  • the present application provides the compound of Formula (I), wherein
  • R 1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, wherein the alkyl or cycloalkyl moiety is optionally substituted with one to three halogen atoms;
  • R 2 is hydrogen
  • R 3 is hydrogen
  • R 4 is hydrogen
  • R 5 is hydrogen
  • R 6 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, wherein the alkyl or cycloalkyl moiety is optionally substituted with one to three halogen atoms;
  • R 7 is hydrogen or C 1 -C 3 alkyl
  • R a and R b combine with the nitrogen atom to which they are attached to form a four to eight member heterocyclic monocyclic group optionally containing an oxygen or a nitrogen atom, or a six to ten member heterocyclic fused or bridged bicyclic or spirocyclic group optionally containing an oxygen or a nitrogen atom in the heterocyclic monocyclic, bicyclic or spirocyclic group, wherein the heterocyclic monocyclic, bicyclic or spirocyclic group is further optionally substituted with one to three members independently selected from C 1 -C 6 alkyl, cyano, oxo, halo, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, OR 11 , C(O)N—R 11 wherein R 11 is hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalky
  • the present application provides the compound of Formula (I), wherein
  • R 1 is C 1 -C 3 haloalkyl or C 3 -C 6 cycloalkyl
  • R 2 is hydrogen
  • R 3 is hydrogen
  • R 4 is hydrogen
  • R 5 is hydrogen
  • R 6 is C 1 -C 3 haloalkyl or C 3 -C 6 cycloalkyl
  • R7 is hydrogen or C 1 -C 3 alkyl
  • R a and R b combine with the nitrogen atom to which they are attached to form a four to eight member heterocyclic monocyclic group optionally containing an oxygen or a nitrogen atom, or a six to ten member heterocyclic fused bicyclic or spirocyclic group optionally containing an oxygen or a nitrogen atom in the heterocyclic monocyclic, bicyclic or spirocyclic group, wherein the heterocyclic monocyclic, bicyclic or spirocyclic group is further optionally substituted with one, two, or three members independently selected from C 1 -C 6 alkyl, hydroxyl, cyano, oxy, halo, C 1 -C 6 carbonyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, C 2 -C 6 heterocycloalkyl, C 1 -C 6 alkyl-R 11 , OR 11 , C(O)NR 11 wherein R 11 is
  • R 1 is methyl, ethyl, propyl, fluoromethyl, fluoroethyl, fluoropropyl, difluoromethyl, difluoroethyl, difluoropropyl, trifluoromethyl, trifluoroethyl, trifluoropropyl, trifluorobutyl, cyclopropyl, cyclobutyl, fluorocyclopropyl, and fluorocyclobutyl;
  • R 2 is hydrogen
  • R 3 is hydrogen
  • R 4 is hydrogen
  • R 5 is hydrogen
  • R 6 is methyl, ethyl, propyl, fluoromethyl, fluoroethyl, fluoropropyl, difluoromethyl, difluoroethyl, difluoropropyl, difluorobutyl, trifluoromethyl, trifluoroethyl, trifluoropropyl, trifluorobutyl, cyclopropyl, cyclobutyl, fluorocyclopropyl, and fluorocyclobutyl;
  • R 7 is hydrogen or methyl
  • R a and R b combine with the nitrogen atom to which they are attached to form a four to seven member heterocyclic monocyclic group optionally containing an oxygen or a nitrogen atom, wherein the heterocyclic monocyclic group is further optionally substituted with one, two, or three members independently selected from methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, propyl, difluoropropyl, trifluoropropyl, cyano, oxo, methoxy, ethoxy, methoxymethyl, methoxyethyl, ethoxymethyl, ethoxyethyl, fluoro, bromo, C(O)NH 2 , C(O)N(CH 3 )H, C(O)N(CH 3 )(CH 3 ), C(O)N(CH 2 CH 3 )H, C(
  • the present application provides the compound of Formula (I), wherein
  • R 1 is methyl, ethyl, propyl, fluoromethyl, fluoroethyl, fluoropropyl, difluoromethyl, difluoroethyl, difluoropropyl, trifluoromethyl, trifluoroethyl, trifluoropropyl, trifluorobutyl, cyclopropyl, cyclobutyl, fluorocyclopropyl, and fluorocyclobutyl;
  • R 2 is hydrogen
  • R 3 is hydrogen
  • R 4 is hydrogen
  • R 5 is hydrogen
  • R 6 is methyl, ethyl, propyl, fluoromethyl, fluoroethyl, fluoropropyl, difluoromethyl, difluoroethyl, difluoropropyl, difluorobutyl, trifluoromethyl, trifluoroethyl, trifluoropropyl, trifluorobutyl, cyclopropyl, cyclobutyl, fluorocyclopropyl, and fluorocyclobutyl;
  • R 7 is hydrogen or methyl
  • R a and R b combine with the nitrogen atom to which they are attached to form a six to nine member heterocyclic fused or bridged bicyclic or spirocyclic group optionally containing an oxygen or a nitrogen atom, wherein the heterocyclic bicyclic group is further optionally substituted with one, two, or three members independently selected from methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, propyl, difluoropropyl, trifluoropropyl, cyano, oxo, methoxy, ethoxy, methoxymethyl, methoxyethyl, fluoro, bromo, C(O)NH 2 , C(O)N(CH 3 )H, C(O)N(CH 3 )(CH 3 ), C(O)N(CH 2 CH 3 )H, C(O)N
  • the present application provides the compound of Formula (I), wherein R 1 is C 1 -C 3 haloalkyl or C 3 -C 6 cycloalkyl, wherein the cycloalkyl group is optionally substituted with one to four halogen atoms.
  • R 1 is selected from the group consisting of trifluoropropyl, trifluoroisopropyl, fluorocyclopropyl, and cyclopropyl.
  • the present application provides the compound of Formula (I), wherein R 2 is hydrogen; R 3 is hydrogen; R 4 is hydrogen; R 5 is hydrogen, and R 7 is hydrogen.
  • the present application provides the compound of Formula (I), wherein R 6 is C 1 -C 3 haloalkyl or C 3 -C 6 cycloalkyl, wherein the cycloalkyl group is optionally substituted with one to four halogen atoms.
  • R 6 is selected from the group consisting of trifluoropropyl, trifluoroisopropyl, fluorocyclopropyl, and cyclopropyl.
  • the present application provides the compound of Formula (I), wherein R a and R b combine with the nitrogen atom to which they are attached to form a heterocyclic group, wherein the heterocyclic group is selected from the group consisting of:
  • heterocyclic group is further optionally substituted with one member or two members, on different atoms or the same atom, independently selected from methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, tri fluoroethyl, propyl, difluoropropyl, trifluoropropyl, cyano, oxo, methoxy, ethoxy, methoxymethyl, methoxyethyl, fluoro, bromo, C(O)NH 2 , C(O)N(CH 3 )H, C(O)N(CH 3 )(CH 3 ), C(O)N(CH 2 CH 3 )H, C(O)N(CH 3 )(CH 2 CH 3 ), and C(O)N(CH 2 CH 3 ) 2 ; or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compounds of the present application include, but are not limited to, those compounds described in Table 1.
  • the present application provides compounds, methods and compositions that use or include a racemic mixture, a mixture containing an enantiomeric excess (e.e.) of one enantiomer, or a mixture containing a diastereoisomeric excess (d.e.) of one diastereoisomer.
  • the compounds of Formula (I) may comprise at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% of one stereoisomer that has the desired ASK-1 activities.
  • the present application provides methods and compositions that use or include optical isomers, racemates, or other mixtures thereof, of the compounds of Formula I or a pharmaceutically acceptable salt, prodrug, or solvate thereof.
  • the single enantiomer or diastereoisomer, i.e., optically active form may be obtained by asymmetric synthesis or by resolution of the racemate. Resolution of racemates may be accomplished, for example, by known methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high pressure liquid chromatography (HPLC) column.
  • HPLC high pressure liquid chromatography
  • ASK1 inhibitors Human patients being treated for an acute cardiovascular disease event by administration of ASK1 inhibitors often exhibit diseases or conditions that benefit from treatment with other therapeutic agents. These diseases or conditions can be of the cardiovascular nature or can be related to pulmonary disorders, metabolic disorders, gastrointestinal disorders and the like. Additionally, some coronary patients being treated for an acute cardiovascular disease event by administration of an ASK1 inhibitor exhibit conditions that can benefit from treatment with therapeutic agents that are antibiotics, analgesics, and/or antidepressants and anti-anxiety agents.
  • Cardiovascular related diseases or conditions that can benefit from a combination treatment of ASK1 inhibitors with one or more other therapeutic agents include, without limitation, angina, including stable angina, unstable angina (UA), exercised-induced angina, variant angina, arrhythmias, intermittent claudication, myocardial infarction including non-STE myocardial infarction (NSTEMI), heart failure including congestive (or chronic) heart failure, acute heart failure, or recurrent ischemia.
  • angina including stable angina, unstable angina (UA), exercised-induced angina, variant angina, arrhythmias, intermittent claudication, myocardial infarction including non-STE myocardial infarction (NSTEMI), heart failure including congestive (or chronic) heart failure, acute heart failure, or recurrent ischemia.
  • UA stable angina
  • UA unstable angina
  • exercised-induced angina variant angina
  • arrhythmias arrhythmias
  • intermittent claudication myocardial infarction
  • Therapeutic agents suitable for treating cardiovascular related diseases or conditions include anti-anginals, heart failure agents, antithrombotic agents, antiarrhythmic agents, antihypertensive agents, and lipid lowering agents.
  • ASK1 inhibitors with therapeutic agents suitable for treating cardiovascular related conditions allows enhancement in the standard of care therapy the patient is currently receiving.
  • Anti-anginals include beta-blockers, calcium channel blockers, and nitrates. Beta blockers reduce the heart's need for oxygen by reducing its workload resulting in a decreased heart rate and less vigorous heart contraction.
  • beta-blockers include acebutolol, atenolol, betaxolol, bisoprolol/hydrochlorothiazide, bisoprolol, carteolol, esmolol, labetalol, metoprolol, nadolol, propranolol, sotalol (Bumblece), and timolol.
  • Nitrates dilate the arteries and veins thereby increasing coronary blood flow and decreasing blood pressure.
  • examples of nitrates include nitroglycerin, nitrate patches, isosorbide dinitrate, and isosorbide-5-mononitrate.
  • Calcium channel blockers prevent the normal flow of calcium into the cells of the heart and blood vessels causing the blood vessels to relax thereby increasing the supply of blood and oxygen to the heart.
  • Examples of calcium channel blockers include amlodipine, bepridil, diltiazem, felodipine, nifedipine, nimodipine (Nimotop), nisoldipine, verapamil, and nicardipine.
  • Agents used to treat heart failure include diuretics, ACE inhibitors, vasodilators, and cardiac glycosides.
  • Diuretics eliminate excess fluids in the tissues and circulation thereby relieving many of the symptoms of heart failure. Examples of diuretics include hydrochlorothiazide, metolazone, furosemide, bumetanide, spironolactone, and eplerenone.
  • Angiotensin converting enzyme (ACE) inhibitors reduce the workload on the heart by expanding the blood vessels and decreasing resistance to blood flow.
  • ACE inhibitors include benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril.
  • Vasodilators reduce pressure on the blood vessels by making them relax and expand.
  • vasodilators include hydralazine, diazoxide, prazosin, clonidine, and methyldopa.
  • ACE inhibitors, nitrates, potassium channel activators, and calcium channel blockers also act as vasodilators.
  • Cardiac glycosides are compounds that increase the force of the heart's contractions. These compounds strengthen the pumping capacity of the heart and improve irregular heartbeat activity. Examples of cardiac glycosides include digitalis, digoxin, and digitoxin.
  • Antithrombotics inhibit the clotting ability of the blood.
  • Platelet inhibitors inhibit the clotting activity of platelets, thereby reducing clotting in the arteries.
  • platelet inhibitors include acetylsalicylic acid, ticlopidine, clopidogrel, dipyridamole, cilostazol, persantine sulfinpyrazone, dipyridamole, indomethacin, and glycoprotein IIb/IIIa inhibitors, such as abciximab, tirofiban, and eptifibatide.
  • Beta blockers and calcium channel blockers also have a platelet-inhibiting effect.
  • Anticoagulants prevent blood clots from growing larger and prevent the formation of new clots.
  • Examples of anticoagulants include bivalirudin, warfarin, unfractionated heparin, low molecular weight heparin, danaparoid, lepirudin, and argatroban.
  • Thrombolytic agents act to break down an existing blood clot.
  • examples of thrombolytic agents include streptokinase, urokinase, and tenecteplase, and tissue plasminogen activator.
  • Antiarrhythmic agents are used to treat disorders of the heart rate and rhythm.
  • Examples of antiarrhythmic agents include amiodarone, procainamide, lidocaine, and propafenone.
  • Cardiac glycosides and beta blockers are also used as antiarrhythmic agents.
  • Antihypertensive agents are used to treat hypertension, a condition in which the blood pressure is consistently higher than normal. Hypertension is associated with many aspects of cardiovascular disease, including congestive heart failure, atherosclerosis, and clot formation.
  • antihypertensive agents include alpha-1-adrenergic antagonists, such as prazosin (Minipress), doxazocin mesylate (Cardura), prazosin hydrochloride (Minipress), prazosin, polythiazide (Minizide), and terazosin hydrochloride (Hytrin); beta-adrenergic antagonists, such as propranolol (Inderal), nadolol (Corgard), timolol (Blocadren), metoprolol (Lopressor), and pindolol (Visken); central alpha-adrenoceptor agonists, such as clonidine hydrochloride (Catapres), clonidine hydrochloride and chlorthalidone (Clorpres, Combipres), guanabenz Acetate (Wytensin), guanfacine hydrochloride (Tenex), methyldopa (Aldomet), methyld
  • Lipid lowering agents are used to lower the amounts of cholesterol or fatty sugars present in the blood.
  • lipid lowering agents include bezafibrate (Bezalip), ciprofibrate (Modalim), and statins, such as atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor, Altocor), mevastatin, pitavastatin (Livalo, Pitava) pravastatin (Lipostat), rosuvastatin (Crestor), and simvastatin (Zocor).
  • statins such as atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor, Altocor), mevastatin, pitavastatin (Livalo, Pitava) pravastatin (Lipostat), rosuvastatin (Crestor), and simvastatin (Zocor).
  • Patients in need of the ASK1 inhibitor often suffers from secondary medical conditions such as one or more of a metabolic disorder, a pulmonary disorder, a peripheral vascular disorder, or a gastrointestinal disorder.
  • secondary medical conditions such as one or more of a metabolic disorder, a pulmonary disorder, a peripheral vascular disorder, or a gastrointestinal disorder.
  • Such patients can benefit from treatment of a combination therapy comprising administering to the patient the compounds of the invention in combination with at least one therapeutic agent.
  • Pulmonary disorder refers to any disease or condition related to the lungs.
  • pulmonary disorders include, without limitation, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema.
  • COPD chronic obstructive pulmonary disease
  • bronchitis bronchitis
  • emphysema emphysema
  • therapeutics agents used to treat pulmonary disorders include bronchodilators including beta2 agonists and anticholinergics, corticosteroids, and electrolyte supplements.
  • Specific examples of therapeutic agents used to treat pulmonary disorders include epinephrine, terbutaline, albuterol, salmeterol, Serevent, theophylline, ipratropium bromide, tiotropium, methylprednisolone, magnesium, and potassium.
  • metabolic disorders include, without limitation, diabetes, including type I and type II diabetes, metabolic syndrome, dyslipidemia, obesity, glucose intolerance, hypertension, elevated serum cholesterol, and elevated triglycerides.
  • therapeutic agents used to treat metabolic disorders include antihypertensive agents and lipid lowering agents, as described in the section “Cardiovascular Agent Combination Therapy” above.
  • Additional therapeutic agents used to treat metabolic disorders include insulin, sulfonylureas, biguanides, alpha-glucosidase inhibitors, and incretin mimetics.
  • Peripheral vascular disorders are disorders related to the blood vessels (arteries and veins) located outside the heart and brain, including, for example peripheral arterial disease (PAD), a condition that develops when the arteries that supply blood to the internal organs, arms, and legs become completely or partially blocked as a result of atherosclerosis.
  • PAD peripheral arterial disease
  • Gastrointestinal disorders refer to diseases and conditions associated with the gastrointestinal tract. Examples of gastrointestinal disorders include gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), gastroenteritis, gastritis and peptic ulcer disease, and pancreatitis.
  • GFD gastroesophageal reflux disease
  • IBD inflammatory bowel disease
  • pancreatitis pancreatitis
  • therapeutic agents used to treat gastrointestinal disorders include proton pump inhibitors, such as pantoprazole (Protonix), lansoprazole (Prevacid), esomeprazole (Nexium), omeprazole (Prilosec), rabeprazole; H2 blockers, such as cimetidine (Tagamet), ranitidine (Zantac), famotidine (Pepcid), nizatidine (Axid); prostaglandins, such as misoprostoL (Cytotec); sucralfate; and antacids.
  • proton pump inhibitors such as pantoprazole (Protonix), lansoprazole (Prevacid), esomeprazole (Nexium), omeprazole (Prilosec), rabeprazole
  • H2 blockers such as cimetidine (Tagamet), ranitidine (Zantac), famotidine (Pepcid), nizatidine (Axid);
  • Analgesics are therapeutic agents that are used to relieve pain.
  • Examples of analgesics include opiates and morphinomimetics, such as fentanyl and morphine; paracetamol; NSAIDs, and COX-2 inhibitors.
  • the compounds of the present application may be used in combination with one or more additional therapeutic agent that are being used and/or developed to treat diseases.
  • the one or more additional therapeutic agent may be an inhibitor to P13K such as PI3K ⁇ , PI3K ⁇ , PI3K ⁇ and/or PI3K ⁇ , Janus kinase (JAK) such as JAK1, JAK2 and/or JAK3, spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), bromodomain containing protein inhibitor (BRD) such as BRD4, a lysyl oxidase protein (LOX), lysyl oxidase-like protein (LOXL) such as LOXL1-5, matrix metalloprotease (MMP) such as MMP 1-10, adenosine A2B receptor (A2B), isocitrate dehydrogenase (IDH) such as IDH1, serine/threonine kinase TPL2, discoidin domain receptor (DDR) such as DDR1 and DDR2, his
  • compositions that contain, as the active ingredient, one or more of the compounds described, or a pharmaceutically acceptable salt, stereoisomer, or ester thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
  • the pharmaceutical compositions may be administered alone or in combination with other therapeutic agents.
  • Such compositions are prepared in a manner well known in the pharmaceutical art (see, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G. S. Banker & C. T. Rhodes, Eds.)
  • compositions may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.
  • agents having similar utilities for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.
  • compositions of the present invention are parenteral, particularly by injection.
  • forms in which the novel compositions of the present invention may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.
  • Aqueous solutions in saline are also conventionally used for injection, but less preferred in the context of the present invention.
  • Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Sterile injectable solutions are prepared by incorporating a compound according to the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral administration is another route for administration of compounds in accordance with the present application. Administration may be via capsule or enteric coated tablets, or the like.
  • the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • compositions described herein can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Pat. Nos. 3,845,770; 4,326,525; 4,902,514; and 5,616,345.
  • Another formulation for use in the methods of the present invention employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
  • the construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
  • compositions are preferably formulated in a unit dosage form.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient (e.g., a tablet, capsule, and ampoule).
  • a suitable pharmaceutical excipient e.g., a tablet, capsule, and ampoule.
  • the compounds are generally administered in a pharmaceutically effective amount.
  • each dosage unit contains from 1 mg to 2 g, 1 mg to 1 g, 1 to 900 mg, 10 to 900 mg, 25 to 900 mg, 50 to 900 mg, 75 to 900 mg, 100 to 900 mg, 150 to 900 mg, 200 to 900 mg, 250 to 900 mg, 300 to 900 mg, 400 to 900 mg, 500 to 900 mg, 600 to 900 mg, 700 to 900 mg, 800 to 900 mg of a compound described herein.
  • each dosage unit contains from 0.1 to 1000 mg, 1 to 900 mg, 1 to 800 mg, 1 to 700 mg, 1 to 600 mg, 1 to 500 mg, 10 to 500 mg, 25 to 500 mg, 50 to 500 mg, 100 to 500 mg, 200 to 500 mg, 300 to 500 mg, 400 to 500 mg of a compound a compound described herein. It will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention.
  • a pharmaceutical excipient for preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention.
  • these pre-formulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • the tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
  • the compounds of the present application may be prepared using methods disclosed herein and routine modifications thereof which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein.
  • the synthesis of typical compounds described herein, e.g. compounds having structures described by one or more of Formula (I), may be accomplished as described in the following Scheme A and or as provided in the following examples. If available, reagents may be purchased commercially, e.g. from Sigma Aldrich or other chemical suppliers.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R a and R b are defined as above.
  • the 4-bromo thiazole carboxylic acid (1) is converted to the carbohydrazide first by conversion to the acyl chloride using an acylhalide forming reagent such as thionyl chloride or oxalyl chloride.
  • the acyl halide is then treated with hydrazine to form the carbohydrazide (2).
  • the carbohydrazide is cyclized in the presence of dimethylformamide dimethylacetal and the appropriately substituted primary amine to afford the triazole (3) having the desired R 1 substituent.
  • the acyl halide is converted to the amine by reaction with an appropriately substituted amine (R 1 NH 2 ) to form the corresponding amide of compound (1).
  • the amide is converted to the thioamide by reaction with Lawesson's reagent using known conditions or as described herein.
  • the thioamide is then reacted with hydrazine to afford the triazole (3).
  • the triazole (3) is converted to the amino analog (intermediate A′) via reaction with copper acetate and ammonium hydroxide in DMF or other solvents known to one of ordinary skill in the art.
  • Preparation of the intermediate C′ is initiated by coupling the compound (4) with an appropriately substituted imidazole having the desired R 6 substituent.
  • the resulting product (5) is carbonylated using palladium reagents such as Pd (dppf)Cl 2 in the presence of carbon monoxide in a protic solvent such as butanol.
  • the resulting acid (6) is isolated as intermediate C′.
  • Intermediate C′ is then reacted with intermediate A′ to form the amide Intermediate D′.
  • Intermediate D′ is subjected to an S N Ar reaction and converted to the desired amine compound of Formula (I).
  • One of ordinary skill in the art is able to perform the reactions herein following the above general scheme, the specific procedures provided herein, or other literature sources known to such an artisan.
  • Typical embodiments of compounds in accordance with the present invention may be synthesized using the general reaction schemes described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Given a desired product for which the substituent groups are defined, the necessary starting materials generally may be determined by inspection. Starting materials are typically obtained from commercial sources or synthesized using published methods. For synthesizing compounds which are embodiments of the present invention, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein.
  • solvent refers to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like).
  • solvents used in the reactions of the present invention are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.
  • Step 6 Preparation of (S)-4-bromo-2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazole
  • Step 7 Preparation of (S)-2-(4-(1,1,1-trifluoropropan-2-yl)-4H-1,2,4-triazol-3-yl)thiazol-4-amine (Intermediate B)
  • 4-(4-cyclopropyl-1H-imidazol-1-yl)-5-fluoropicolinate (640 mg, 2.11 mmol) was dissolved in 1N HCl (5 mL) and the reaction was heated to 100° C. overnight. The solvent was removed, CH 3 CN was added and the solvent removed to afford 4-(4-cyclopropyl-1H-imidazol-1-yl)-5-fluoropicolinic acid which was used in subsequent reactions.
  • R a , R b , and R 1 are defined in Formula (I).
  • the compounds of Formula I are believed effective in the treatment of conditions that respond to administration of ASK1 inhibitors.
  • the compounds of Formula I are useful in the treatment of a broad range of diseases, for example autoimmune disorders, inflammatory diseases, cardiovascular diseases (including diabetes, diabetic nephropathy, and other complications of diabetes), cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases (including COPD, idiopathic pulmonary fibrosis (IPF), and acute lung injury), acute and chronic liver diseases, and neurodegenerative diseases.
  • diseases for example autoimmune disorders, inflammatory diseases, cardiovascular diseases (including diabetes, diabetic nephropathy, and other complications of diabetes), cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases (including COPD, idiopathic pulmonary fibrosis (IPF), and acute lung injury), acute and chronic liver diseases, and neurodegenerative diseases.
  • cardiovascular diseases including diabetes, diabetic nephropathy, and other complications of diabetes
  • cardio-renal diseases including kidney disease, fibrotic diseases, respiratory diseases (
  • TR-FRET ASK1 Apoptosis Signal-Regulating Kinase 1
  • ASK1 Apoptosis Signal-regulating Kinase 1
  • TR-FRET ASK1 kinase assay which determined the amount of phosphate transferred to a peptide substrate from ATP.
  • Dephosphorylated recombinant human ASK1 kinase was from Gilead Sciences.
  • Small molecule kinase inhibitor staurosporine (Catalogue #S6942) and dithiothreitol (DTT, catalogue #43815-5G) were obtained from Sigma Chemicals (St. Louis, Mo.).
  • ATP catalogue #7724
  • test compounds were from Gilead Sciences.
  • HTRF KinEASETM-STK S3 kit was obtained from Cisbio (Bedford, Mass.). All other reagents were of the highest grade commercially available.
  • the assay measures the phosphorylation level of a biotinylated peptide substrate by the ASK1 kinase using HTRF detection.
  • This is a competitive, time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay, based on HTRF® KinEASETM-STK manual from Cisbio.
  • Test compound 1 ⁇ M STK3 peptide substrate, 4 nM of ASK1 kinase were incubated with 10 mM MOP buffer, pH.
  • the fluorescence was measured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665 nm/615 nm was calculated for each well.
  • the resulting TR-FRET level (a ratio of 665 nm/615 nm) was proportional to the phosphorylation level.
  • the degree of phosphorylation of peptide substrate was linear with time and concentration for the enzyme.
  • the assay system yielded consistent results with regard to K m and specific activities for the enzyme. For inhibition experiments (IC 50 values), activities were performed with constant concentrations of ATP, peptide and several fixed concentrations of inhibitors. Staurosporine, the nonselective kinase inhibitor, was used as the positive control. All enzyme activity data are reported as an average of quadruplicate determination.
  • the cellular potency (i.e. EC 50 ) of compounds is determined in cells that stably express an AP-1: luciferase reporter construct (293/AP1-Luc cells—Panomics Inc., 6519 Dumbarton Circle, Fremont, Calif.).
  • Cells are infected with an adenovirus expressing kinase active ASK1 (631-1381 of rat ASK1 cDNA), which will activate the AP-1 transcription factor and increase the expression of luciferase.
  • Inhibitors of ASK1 will decrease the enzyme activity of ASK1 and therefore decrease the activity of AP-1 transcription factor and the expression of luciferase.
  • the results will be used to determine the in vivo potency inhibitors of ASK1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US15/105,372 2013-12-20 2014-12-15 Apoptosis signal-regulating kinase inhibitors Active US9908875B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/105,372 US9908875B2 (en) 2013-12-20 2014-12-15 Apoptosis signal-regulating kinase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361918784P 2013-12-20 2013-12-20
PCT/US2014/070362 WO2015095059A1 (en) 2013-12-20 2014-12-15 Apoptosis signal-regulating kinase inhibitors
US15/105,372 US9908875B2 (en) 2013-12-20 2014-12-15 Apoptosis signal-regulating kinase inhibitors

Publications (2)

Publication Number Publication Date
US20160318922A1 US20160318922A1 (en) 2016-11-03
US9908875B2 true US9908875B2 (en) 2018-03-06

Family

ID=52282961

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/570,655 Active US9169243B2 (en) 2013-12-20 2014-12-15 Apoptosis signal-regulating kinase inhibitors
US15/105,372 Active US9908875B2 (en) 2013-12-20 2014-12-15 Apoptosis signal-regulating kinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/570,655 Active US9169243B2 (en) 2013-12-20 2014-12-15 Apoptosis signal-regulating kinase inhibitors

Country Status (23)

Country Link
US (2) US9169243B2 (ro)
EP (1) EP3083615B1 (ro)
JP (3) JP2016540029A (ro)
KR (1) KR20160098463A (ro)
CN (1) CN105980382A (ro)
AP (1) AP2016009248A0 (ro)
AU (1) AU2014366235B2 (ro)
CA (1) CA2934454C (ro)
CL (1) CL2016001538A1 (ro)
CR (1) CR20160268A (ro)
CU (1) CU20160095A7 (ro)
DO (1) DOP2016000136A (ro)
EA (1) EA201690973A1 (ro)
ES (1) ES2731703T3 (ro)
HK (2) HK1224284A1 (ro)
IL (1) IL245807A0 (ro)
MD (1) MD4658B1 (ro)
MX (1) MX2016008254A (ro)
NZ (1) NZ720660A (ro)
PE (1) PE20160859A1 (ro)
PH (1) PH12016501149A1 (ro)
SG (1) SG11201604473VA (ro)
WO (1) WO2015095059A1 (ro)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10307427B2 (en) 2012-12-21 2019-06-04 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EA023040B1 (ru) * 2010-07-02 2016-04-29 Джилид Сайэнс, Инк. Ингибиторы киназ, регулирующих апоптозный сигнал
EP3152198B1 (en) * 2014-06-09 2019-02-27 Takeda Pharmaceutical Company Limited Radiolabeled compounds
CN110036005B (zh) * 2016-11-16 2022-09-27 广东东阳光药业有限公司 酰胺衍生物及其在药物中的应用
WO2018094964A1 (zh) * 2016-11-25 2018-05-31 武汉大学 一种以凋亡信号调节激酶1n端二聚化为靶点筛选用于治疗脂肪性肝炎药物的方法
CN109963570A (zh) 2017-01-21 2019-07-02 宁波知明生物科技有限公司 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用
CA3050346C (en) * 2017-01-22 2020-07-14 Fujian Cosunter Pharmaceutical Co., Ltd. Pyridine derivative as ask1 inhibitor and preparation method and use thereof
CN115504986B (zh) 2017-03-03 2024-05-14 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
AU2018266911C1 (en) 2017-05-12 2022-10-20 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10246439B2 (en) 2017-05-25 2019-04-02 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218042A1 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218051A1 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019046186A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF
CN109232538B (zh) * 2017-10-12 2020-07-24 深圳市塔吉瑞生物医药有限公司 一种1,2,4-三氮唑类化合物
EP3735404B1 (en) 2018-01-02 2023-11-29 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
US10683289B2 (en) 2018-05-02 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
BR112020022114A2 (pt) * 2018-05-02 2021-01-26 Enanta Pharmaceuticals, Inc. tetrazol contendo inibidores de quinase-1 reguladora de sinal de apoptose e métodos de uso do mesmo
SG11202012784SA (en) * 2018-06-27 2021-01-28 Biogen Ma Inc Ask1 inhibiting agents
US10968199B2 (en) 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11345699B2 (en) 2018-11-19 2022-05-31 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020198214A1 (en) 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003387A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
WO2014100541A1 (en) 2012-12-21 2014-06-26 Gilead Sciences, Inc. Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003387A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
WO2014100541A1 (en) 2012-12-21 2014-06-26 Gilead Sciences, Inc. Substituted pyridine-2-carboxamide compounds as apoptosis signal-regulating kinase inhibitors
US9051313B2 (en) * 2012-12-21 2015-06-09 Gildead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
US20150246910A1 (en) * 2012-12-21 2015-09-03 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
Hattori, K. et al. (2009) "The Roles of ASK family proteins in stress response and diseases" Cell Comm. and Signaling 7:9:1-10.
Ichijo, H. et al. (1997) "Induction of Apoptosis by ASK1, a Mammalian MAPKKK That Activates SAPK/JNK and p38 Signaling Pathways" Science vol. 275:90-94.
International Search Report-Written Opinion dated Feb. 12, 2015 for PCT/US2014/070362.
International Search Report—Written Opinion dated Feb. 12, 2015 for PCT/US2014/070362.
Iriyama, T. et al. (2009) "ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis" The EMBO Journal 28:843-853.
Kumar, S. et al. (2003) "P38 MAP Kinases: Key Signalling Molecules as Therapeutic Targets for Inflammamatory Diseases" Nature Reviews Drug Discovery vol. 2:717-726.
Nagai, H. et al, (2007) "Pathophysiological Roles of ASK 1-MAP Kinase Signaling Pathways" J. Biochem. Mol. Biol. vol. 40:1:1-6.
Pimienta G. et al. (2007) "Canonical and Alternative MAPK Signaling" Cell Cycle 6:21:2628-2632.
Saitoh, M. et al. (1998) "Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1" EMBO J. vol. 17:9:2596-2606.
Takeda, K. et al. (2007) "Apoptosis Signal-regulating Kinase (ASK) 2 Functions as a Mitogen-activated Protein Kinase Kinase Kinase in a Heteromeric Complex with ASK1*" J. Biol. Chem. vol. 282:10:7522-7531.
Takeda, K. et al. (2007) "Apoptosis Signal-Regulating Kinase 1 in Stress and Immune Response" Annu. Rev. Pharmacol. Toxicol. 48:8.1-8.27.
Terada. Y. et al. (2007) "Important role of apoptosis signal-regulating kinase 1 in ischemic acute kidney injury" BBRC 364:1043-1049.
Wang: X. et al. (1998) MAPKKK6, a Novel Mitogen-Activated Protein Kinase Kinase Kinase, That Associates with MAPKKK5* Biochem. Biophys. Res. Commun. 253:33-35.
Watanabe, T. et al. (2005) "Apoptosis signal-regulating kinase 1 is involved not oniy in apoptosis but also in non-apoptotic cardiomyocyte death" BBRC 333:562-567.
Zhang, L. et al. (1999) "Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins" Proc. Natl. Acad. Sci. USA vol. 96:8511-8515.
Zhang, Q. et al. (2003) "Delayed activation and regulation of MKK7 in hippocampal CA1 region following global cerebral ischemia in rats" Life Sci 74:37-45.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10307427B2 (en) 2012-12-21 2019-06-04 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors

Also Published As

Publication number Publication date
CU20160095A7 (es) 2016-11-29
WO2015095059A1 (en) 2015-06-25
HK1224284A1 (zh) 2017-08-18
EP3083615B1 (en) 2019-04-17
CL2016001538A1 (es) 2016-10-28
PE20160859A1 (es) 2016-09-18
AU2014366235A1 (en) 2016-06-16
CN105980382A (zh) 2016-09-28
ES2731703T3 (es) 2019-11-18
AP2016009248A0 (en) 2016-05-31
NZ720660A (en) 2018-01-26
MD4658B1 (ro) 2019-11-30
SG11201604473VA (en) 2016-07-28
MD20160069A2 (ro) 2016-11-30
EA201690973A1 (ru) 2016-11-30
IL245807A0 (en) 2016-08-02
US20150175597A1 (en) 2015-06-25
JP6509968B2 (ja) 2019-05-08
HK1226073A1 (zh) 2017-09-22
JP2016540029A (ja) 2016-12-22
PH12016501149A1 (en) 2016-08-22
CR20160268A (es) 2016-08-16
KR20160098463A (ko) 2016-08-18
DOP2016000136A (es) 2016-06-30
JP2019077719A (ja) 2019-05-23
US9169243B2 (en) 2015-10-27
US20160318922A1 (en) 2016-11-03
JP2017193592A (ja) 2017-10-26
MX2016008254A (es) 2016-10-14
CA2934454A1 (en) 2015-06-25
CA2934454C (en) 2019-03-26
EP3083615A1 (en) 2016-10-26
AU2014366235B2 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
US9908875B2 (en) Apoptosis signal-regulating kinase inhibitors
US10307427B2 (en) Apoptosis signal-regulating kinase inhibitors
USRE48150E1 (en) Apoptosis signal-regulating kinase inhibitors
OA17775A (en) Apoptosis signal-regulating kinase inhibitors.

Legal Events

Date Code Title Description
AS Assignment

Owner name: GILEAD SCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOTTE, GREGORY;REEL/FRAME:042400/0178

Effective date: 20150325

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4